Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Primary objectives are to evaluate the safety profile and tolerability of oral BCX1777 in
each cohort of patients with recurrent or refractory T/NK-cell malignancies and to evaluate
pharmacokinetics (PK) of oral BCX1777.